Home | Site Map | Contact
You are here: Home » PBL News » 2019 News

2019 News

September 2019

Procarta Biosystems receives an award from CARB-X of up to $9.2 million to develop new antibiotics to combat antimicrobial resistance

Procarta Biosystems Ltd, a PBL and John Innes Centre spin-out company, announces that it is to receive up to $9.2 million from CARB-X for the development of a new class of antibiotics using its proprietary Oligonucleotide Antimicrobial Discovery platform to target life-threatening drug-resistant pathogens.

Please click here for the full press release.


Back to top

May 2019

Plant Bioscience Ltd transfers control of Hypertrans® plant-based biologics and vaccines expression technology to Leaf Expression Systems Ltd

Plant Bioscience Ltd (PBL) and Leaf Expression Systems Ltd (Leaf) are delighted to announce a further development in their relationship, with PBL granting Leaf the exclusive rights to sub-license the Hypertrans® transient expression system, the core technology underpinning Leaf’s biologics and vaccines contract development and manufacturing services business. Apart from rights previously granted to PBL’s pre-existing licensees, this effectively transfers to Leaf full control of the Hypertrans® technology andassociated patented intellectual property. This extension of Leaf’s rights will ensure that Leaf’s clients are able to use Hypertrans® for the manufacture of their products in multiple geographical locations to meet the needs of individual markets and to enable clients to take advantage of lower manufacturing costs in some of these markets.

Please click here for the full press release.

For more information, please email info@pbltechnology.com.

Back to top

April 2019

Crop enhancing BLINK technology published in SCIENCE

A team at the University of Glasgow has developed a technology which enables plants to better use water resources and enhance photosynthetic efficiency.  The approach accelerates the kinetics of stomatal opening and closure, thus promoting a rapid transition to carbon assimilation under high-light light intensities, while maintaining plant water status when carbon demand is low.  PBL has patented the technology on behalf of the University of Glasgow and is offering licences to the crop industry.

Links: SCIENCE article; BBSRC news.

For enquiries regarding this technology (PBL Tech 19.651),  please contact Plant Bioscience Limited on +44 (0)1603 456500, or via email info@pbltechnology.com.


Back to top

April 2019

Georgina Pope joins PBL

PBL announces that it has appointed Dr Georgina Pope to the position of Technology Transfer Business Development Manager effective 24 June 2019. Georgina will assume lead responsibility for PBL’s Health, Nutrition and Biotechnology portfolio from Dr Martin Stocks, who is leaving PBL to join Procarta Biosystems Limited, one of the new life science companies established by PBL and partners on the Norwich Research Park (NRP).

Georgina has been an Intellectual Property Manager, at the University of East Anglia, since 2010, where as an integral member of the University’s technology transfer management team she has managed the protection and commercialisation of intellectual property across the University, responsible for delivering commercial revenue and impact through the development, funding and management of research outputs, through licensing and spin-out company formation. In that time Georgina has held various company board positions including Director of Iceni Advisory Limited and institutional representative on the Iceni Seedcorn Fund Investment Executive. From 2002 to 2010, Georgina held the position of Industry Liaison Manager at Quadram Institute Bioscience, formerly the Institute of Food Research, a business development role where she developed, promoted and exploited research outputs.  Georgina has a background in life science research and holds a PhD in Microbiology from the University of Kent. 

PBL’s Managing Director, Dr Jan Chojecki said “Georgina is a highly regarded member of the NRP enterprise community and she has a wealth of experience in commercialisation of early stage life science innovations. We are really delighted to welcome her to the PBL team.”

Back to top

February 2019

New low-gliadin wheat acceptable to people with gluten sensitivity and also shows potential beneficial effects on the gut microbiome, compared with a gluten-free diet

Aiming for a wheat that is safe for people with coeliac disease and other gluten-sensitive individuals to consume, Professor Francisco Barro and colleagues of the CSIC Institute for Sustainable Agriculture in Cordoba, Spain have developed transgenic wheat lines in which the gliadin proteins (the gluten elements responsible for the damaging immune response of people with coeliac disease) have been strongly, and specifically, supressed.

Now, a study published in December 2018 in the journal Nutrients  has shown that fresh bread, made from the new wheat line, causes no negative response in non-coeliac gluten sensitive (NCGS) individuals when consumed regularly over several days.  The bread was considered highly palatable by the trial participants. Moreover, in addition to the success in not triggering any acute gut symptoms, analysis of gut microbial populations demonstrated that the low-gliadin bread caused clear changes in the microbial profile consistent with a more beneficial population of natural bacteria, when compared to the profile present whilst consuming a gluten-free diet.

Please click here to read the article in full.

For enquiries regarding the low-gliadin wheat (PBL Tech 10.512), please contact Plant Bioscience Limited on +44 (0)1603 456500, or via email info@pbltechnology.com.

Back to top

News Archive:
Latest News
2019 News
2018 News
2017 News
2016 News
2015 News
2014 News
2013 News
2012 News
2011 News
2010 News
2009 News
2008 News
2007 News
2006 News
2005 News
2004 News
2003 News
2002 News
2001 News
2000 News

Back to top